The company’s pharmaceuticals growth is driven by market share gains for its blockbuster drugs, Darzalex, Stelara, and Tremfya. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. With higher inflation and the Fed raising interest rates, among other factors, Pfizer stock has seen an 8% fall this year.